In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68.
MX-68 is a newly synthesized anti-folate, chemically designed not to undergo intracellular polyglutamation and to have increased affinity to dihydrofolate reductase (DHFR). In the present study, we examined the in vitro and in vivo biological activities of MX-68 compared with methotrexate (MTX) which forms several polyglutamates intracellularly. MX-68 dose-dependently inhibited the proliferation of PHA-, anti-CD3-, or PMA plus ionomycin-stimulated peripheral blood mononuclear cells (PBMC) and endothelial cells (EC) from normal subjects as well as IL-1 beta- or TNF alpha-stimulated synovial fibroblastic cells (SC) from rheumatoid arthritis (RA) patients. Coaddition of folinic acid completely reversed the anti-proliferative effects of both MX-68 and MTX. Although the anti-proliferative activities of MX-68 were almost comparable to those of MTX, the washout study clearly showed the characteristic nature of MX-68. When drugs were removed during culture, the suppressive effect of MX-68 completely disappeared, whereas suppression by MTX was merely weakened. MX-68 dramatically suppressed the onset of collagen-induced arthritis (CIA) in mice when the drug was orally administered three times a week. starting from the day of first immunization. In this model, 2 mg/kg of MX-68 was sufficient to completely suppress arthritis, whereas suppression by the same dose of MTX was partial. These lines of evidence suggest that polyglutamation is not always a prerequisite in the anti-rheumatic effects of anti-folate. In addition, since intracellular accumulation of polyglutamates is thought to have adverse effects, MX-68 may become a more potent and less toxic anti-rheumatic drug than MTX.
Fuji-Gotemba Research Laboratories Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan.
M
M
Mihara
K
K
Urakawa
N
N
Takagi
Y
Y
Moriya
Y
Y
Takeda
D015074:2-Aminoadipic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D000818:Animals; D001169:Arthritis, Experimental / Q000139:chemically induced; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003094:Collagen / Q000633:toxicity; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D005347:Fibroblasts / Q000187:drug effects; D005493:Folic Acid Antagonists / Q000138:chemical synthesis / Q000378:metabolism*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D008727:Methotrexate / Q000031:analogs & derivatives* / Q000378:metabolism*; D051379:Mice; D011099:Polyglutamic Acid / Q000378:metabolism*; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism
D005493:Folic Acid Antagonists; C104193:N-(1-((2,4-diamino-6-pteridinyl)methyl)-3,4-dihydro -2H-1,4-benzothiazine-7-carbonyl)-L-2-aminoadipic acid; D015074:2-Aminoadipic Acid; D011099:Polyglutamic Acid; D003094:Collagen; D013762:Tetrahydrofolate Dehydrogenase; D008727:Methotrexate